These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

182 related articles for article (PubMed ID: 28497462)

  • 1. Skin hyperpigmentation following intravenous polymyxin B treatment associated with melanocyte activation and inflammatory process.
    Mattos KPH; Cintra ML; Gouvêa IR; Ferreira LÁ; Velho PENF; Moriel P
    J Clin Pharm Ther; 2017 Oct; 42(5):573-578. PubMed ID: 28497462
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Polymyxin B clinical outcomes: A prospective study of patients undergoing intravenous treatment.
    Mattos KPH; Gouvêa IR; Quintanilha JCF; Cursino MA; Vasconcelos PENS; Moriel P
    J Clin Pharm Ther; 2019 Jun; 44(3):415-419. PubMed ID: 30666679
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Polymyxin B-induced skin hyperpigmentation: a rare case report and literature review.
    Zheng G; Cao L; Che Z; Mao E; Chen E; He J
    BMC Pharmacol Toxicol; 2018 Jul; 19(1):41. PubMed ID: 29973293
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Acquired skin hyperpigmentation following intravenous polymyxin B treatment: a cohort study.
    Mattos KP; Lloret GR; Cintra ML; Gouvêa IR; Betoni TR; Mazzola PG; Moriel P
    Pigment Cell Melanoma Res; 2016 May; 29(3):388-90. PubMed ID: 26909746
    [No Abstract]   [Full Text] [Related]  

  • 5. Histopathological findings of pigmented lesion and recovery of natural skin colour in a patient with polymyxin B-associated diffuse hyperpigmentation.
    Zavascki AP; Schuster LF; Duquia RP
    Int J Antimicrob Agents; 2016 Nov; 48(5):579-580. PubMed ID: 27720305
    [No Abstract]   [Full Text] [Related]  

  • 6. Polymyxin B-induced skin hyperpigmentation.
    Li YM; Milikowski C; Selvaggi G; Abbo LM; Skiada D; Galimberti F
    Transpl Infect Dis; 2020 Oct; 22(5):e13312. PubMed ID: 32386075
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Combination therapy with polymyxin B for the treatment of multidrug-resistant Gram-negative respiratory tract infections.
    Sobieszczyk ME; Furuya EY; Hay CM; Pancholi P; Della-Latta P; Hammer SM; Kubin CJ
    J Antimicrob Chemother; 2004 Aug; 54(2):566-9. PubMed ID: 15269195
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Hyperpigmentation on head and neck caused by polymyxin B: A rare case.
    Kaya F; Tuğcugil E
    Niger J Clin Pract; 2023 Sep; 26(9):1393-1395. PubMed ID: 37794556
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Parenteral polymyxin B use in patients with multidrug-resistant gram-negative bacteremia and urinary tract infections: a retrospective case series.
    Pastewski AA; Caruso P; Parris AR; Dizon R; Kopec R; Sharma S; Mayer S; Ghitan M; Chapnick EK
    Ann Pharmacother; 2008 Sep; 42(9):1177-87. PubMed ID: 18664609
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Polymyxin B Induced Generalized Hyperpigmentation in Neonates.
    Gothwal S; Meena K; Sharma SD
    Indian J Pediatr; 2016 Feb; 83(2):179-80. PubMed ID: 26088547
    [No Abstract]   [Full Text] [Related]  

  • 11. Polymyxin B for the treatment of multidrug-resistant pathogens: a critical review.
    Zavascki AP; Goldani LZ; Li J; Nation RL
    J Antimicrob Chemother; 2007 Dec; 60(6):1206-15. PubMed ID: 17878146
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Salvage treatment of pneumonia and initial treatment of tracheobronchitis caused by multidrug-resistant Gram-negative bacilli with inhaled polymyxin B.
    Pereira GH; Muller PR; Levin AS
    Diagn Microbiol Infect Dis; 2007 Jun; 58(2):235-40. PubMed ID: 17350201
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Higher incidence of neurotoxicity and skin hyperpigmentation in renal transplant patients treated with polymyxin B.
    Zhou Y; Li Y; Xie X; Song L; Lan G; Sun B; Tang T; Yan H; Zhang B; Xu P
    Br J Clin Pharmacol; 2022 Nov; 88(11):4742-4750. PubMed ID: 35508710
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Polymyxin B for Gram Negative Multidrug Resistant Bacteria in a Hispanic Population.
    De León-Borrás R; Sánchez-Sergentón C; Mayor-Becerra A; Laureano-Cuadrado AF
    P R Health Sci J; 2019 Mar; 38(1):15-21. PubMed ID: 30924910
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Colistin and polymyxin B in critical care.
    Michalopoulos A; Falagas ME
    Crit Care Clin; 2008 Apr; 24(2):377-91, x. PubMed ID: 18361952
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical use of intravenous polymyxin B for the treatment of patients with multidrug-resistant Gram-negative bacterial infections: An evaluation of the current evidence.
    Falagas ME; Kyriakidou M; Voulgaris GL; Vokos F; Politi S; Kechagias KS
    J Glob Antimicrob Resist; 2021 Mar; 24():342-359. PubMed ID: 33486122
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Outcome of intravenous and inhaled polymyxin B treatment in patients with multidrug-resistant gram-negative bacterial pneumonia.
    Ding P; Li H; Nan Y; Liu C; Wang G; Cai H; Yu W
    Int J Antimicrob Agents; 2024 Oct; 64(4):107293. PubMed ID: 39094752
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Polymyxin B: a new strategy for multidrug-resistant Gram-negative organisms.
    Yuan Z; Tam VH
    Expert Opin Investig Drugs; 2008 May; 17(5):661-8. PubMed ID: 18447592
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Predictors of polymyxin B treatment failure in Gram-negative healthcare-associated infections among critically ill patients.
    Ismail B; Shafei MN; Harun A; Ali S; Omar M; Deris ZZ
    J Microbiol Immunol Infect; 2018 Dec; 51(6):763-769. PubMed ID: 28716359
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacokinetics of intravenous polymyxin B in critically ill patients.
    Zavascki AP; Goldani LZ; Cao G; Superti SV; Lutz L; Barth AL; Ramos F; Boniatti MM; Nation RL; Li J
    Clin Infect Dis; 2008 Nov; 47(10):1298-304. PubMed ID: 18840079
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.